Bernard Ravina - Jan 7, 2022 Form 4 Insider Report for Praxis Precision Medicines, Inc. (PRAX)

Role: Chief Medical Officer
Signature: /s/ Alex Nemiroff, as Attorney-in-Fact
Stock symbol: PRAX
Transactions as of: Jan 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/11/2022, 03:08 PM
Next filing: Feb 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRAX	Common Stock	Award	$0	+22K	+27.32%	$0.00	103K	Jan 7, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRAX	Stock Option (Right to Buy)	Award	$0	+77K		$0.00	77K	Jan 7, 2022	Common Stock	77K	$18.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Dr. Ravina was awarded 22,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on January 7, 2023, subject to the reporting person's continued service through each vesting date. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2	The shares underlying this stock option vest over a four-year period, with 25% vesting on January 7, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Content

Dr. Ravina was awarded 22,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on January 7, 2023, subject to the reporting person's continued service through each vesting date. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

The shares underlying this stock option vest over a four-year period, with 25% vesting on January 7, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.